SCHEMBL5724610

SCHEMBL5724610

CC(=O)SC1CN(c2nc(C(=O)N3CCC3)cs2)C1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
GFER P55789 2/20 0.39
MEN1 O00255 2/20 0.38
HTR2C P28335 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TRPC3 Q13507 3/20 0.36
TRPC6 Q9Y210 3/20 0.36
HRH3 Q9Y5N1 3/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723784 0.98 KMT2A (0.40) KMT2AGFERMEN1HTR2CNPC1
SCHEMBL5724499 0.96 KMT2A (0.42) KMT2AGFERMEN1HTR2CNPC1
SCHEMBL5724329 0.91 HPGD (0.35) KMT2AGFERHPGDRAB9ATRPC3
SCHEMBL5724062 0.91 TSHR (0.41) KMT2AGFERNPC1HPGDRAB9A
SCHEMBL5723626 0.90 HTR2C (0.46) HTR2CALDH1A1RAB9AHSD17B10L3MBTL1
SCHEMBL5724468 0.85 HRH3 (0.37) KMT2AGFERMEN1TRPC3TRPC6
SCHEMBL5724059 0.82 HRH3 (0.44) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL5725358 0.82 HTR2C (0.42) KMT2AGFERMEN1HTR2CNPC1
SCHEMBL5724215 0.80 OGA (0.42) NPC1HPGDRAB9AL3MBTL1GAA
SCHEMBL5724125 0.80 OGA (0.42) KMT2AMEN1NPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD KMT2A 2404/4885GFER 4118/4885MEN1 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.